On November 4, 2021 Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, reported its participation at these upcoming investor conferences (Press release, Nkarta, NOV 4, 2021, View Source [SID1234594570]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen 5TH Annual IO Next Summit
November 15, 2021
11:15 a.m. ET – fireside chat presentation

Stifel 2021 Virtual Healthcare Conference
November 17, 2021
2:00 p.m. ET – fireside chat presentation

Evercore ISI 4TH Annual HealthCONx Conference
December 1, 2021
4:20 p.m. ET – fireside chat presentation

A simultaneous webcast of the presentations will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately four weeks.

On November 4, 2021 Grey Wolf Therapeutics, a biotechnology company spearheading a new therapeutic approach to immuno-oncology driven by targeted neoantigen generation, reported that preclinical in vivo data on the company’s first-in-class inhibitors of ERAP1 will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, Grey Wolf Therapeutics, NOV 4, 2021, View Source [SID1234594569]). Presented findings will highlight the ability of the company’s novel ERAP1 inhibitors to significantly increase the diversity of T cell receptors in the tumor, drive synergistic upregulation of translationally relevant immune markers that have been shown to correlate with patient response to checkpoint inhibition, and trigger significantly greater T cell infiltration into tumors in preclinical models. Additionally, the presentation will showcase significant tumor growth inhibition in syngeneic mouse tumor models following combination of ERAP1 inhibition with an anti-PD-1 antibody. The SITC (Free SITC Whitepaper) conference is being held November 10-14, 2021 in Washington, D.C., as well as virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Grey Wolf Therapeutics’ first-of-its-kind immuno-oncology approach is centered on dramatically increasing the visibility of tumors to allow for their identification and destruction by the body’s immune system. This is achieved through targeted inhibition of the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), causing the generation and presentation of novel and potent neoantigens to the surface of tumor cells. The appearance of these neoantigens uncloaks the tumor cells, illuminating them for the immune system and setting in motion powerful, differentiated T cell responses against the tumor. Importantly, this unique approach is orthogonal to a broad range of other cancer therapy modalities, including, but not limited to, immunotherapy. The company is developing a portfolio of ERAP inhibitors that it believes represents the first ever application of direct neoantigen generation to the treatment of cancer. GRWD5769, the company’s lead ERAP1 inhibitor development candidate, is expected to enter the clinic in the second half of 2022.

Details of the company’s presentation at the 2021 SITC (Free SITC Whitepaper) conference are as follows:

Poster Presentation #553:

Title: First-in-Class Inhibitors of ERAP1 Alter the Immunopeptidome of Cancer, Driving a Differentiated T Cell Response Leading to Tumor Growth Inhibition
Presenting Author: Peter Joyce, Ph.D., Chief Executive Officer of Grey Wolf Therapeutics
Date/Time: Friday, November 12, 2021, 7:00 a.m. – 8:30 p.m. Eastern
Location: Poster Hall – Hall E
The poster will be available for download (upon request) here following the annual meeting.

On November 4, 2021 Primmune Therapeutics reported that it has received $8.4 million in a second tranche of the Company’s Series A financing. The total proceeds for the equity raised in the Series A was $31.4 million (Press release, Primmune Therapeutics, NOV 4, 2021, View Source [SID1234594568]). These funds will be used to support the further clinical development of PRTX007 as a TherAjuvant for acute viral diseases, pre-cancerous lesions, and advanced cancer. PRTX007 is a novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonist that has both therapeutic and adjuvant properties.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Given the initial results from our Phase 1 study in healthy volunteers, we achieved our target clinical milestone that triggered a second tranche of $8.4 million from our existing investors. These funds will be used to set the stage for Primmune’s expansion into multiple definitive efficacy studies," said Charlie McDermott, Chairman and Chief Executive Officer of Primmune Therapeutics. "In 2022, we intend to study PRTX007 in ambulatory respiratory syncytial virus (RSV), outpatient SARS-CoV-2, human papilloma virus (HPV) driven high-grade squamous intraepithelial lesions (HSIL) of the cervix, and in the neo-adjuvant setting in combination with checkpoint inhibitors in advanced cancer."

About TherAjuvants
Primmune Therapeutics coined the term TherAjuvants to reference its lead candidate PRTX007, a toll-like receptor 7 (TLR7) agonist with a combination of therapeutic and adjuvant mechanisms of action. PRTX007 is designed to provide immediate benefit to patients through controlled stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses. PRTX007 uniquely engages TLR7 and targeted immune cells without exacerbating inflammation, a critical feature in treating respiratory viral infections. TherAjuvants differ from therapeutic vaccines in that the source of the antigens presented to the patient’s immune system come from the treated pathology. Additionally, TherAjuvants differ from most small molecule approaches in that they target the patient’s immune system and not tumor cells or virally encoded targets.

On November 4, 2021 Plexium Inc., (Plexium), a leading next-generation targeted protein degradation (TPD) company, reported the appointment of experienced biopharmaceutical leader Percival Barretto-Ko as President and Chief Executive Officer and a member of the Board of Directors (Press release, Plexium, NOV 4, 2021, View Source [SID1234594567]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Barretto-Ko joins Plexium following a sixteen-year tenure with Astellas Pharma Inc., a global pharmaceutical company, where he held several prominent roles and was most recently Chief Business Officer and a member of the Executive Committee where he led the execution of Astellas’ Corporate Strategic Plan.

"Percival is a highly accomplished veteran with the leadership, track record and breadth of experience that make him uniquely suited to lead Plexium," said Mike Grey, Executive Chairman of Plexium. "I look forward to working with Percival to advance the company’s promising drug discovery programs against challenging targets utilizing Plexium’s best-in-class technology."

"I am delighted to join Plexium at this exciting stage, and help achieve its aspiration to be the premier, next generation TPD company. Plexium is well-positioned for success, with its comprehensive proprietary platform, novel approach, top-tier investors, and a world-class team, to create TPD therapies that address the limitations of PROTACs and cereblon," said Mr. Barretto-Ko. "I look forward to advancing the important and innovative work we’re doing to advance protein degraders as a new class of medicines with the potential to treat a wide range of diseases."

Prior to serving as CBO for Astellas Pharma, Mr. Barretto-Ko was President, Astellas Pharma US, where he was responsible for United States operations with annual revenues of over $4.5 billion and more than 3,000 employees. Mr. Barretto-Ko’s earlier roles at Astellas include Senior Vice President, Head of International, and Senior Vice President, Corporate Strategy, Business Development & Government Affairs. Mr. Barretto-Ko joined Astellas in 2005 in London where he served in several roles including EMEA Head of Corporate Strategy, Business Development, and Corporate Communications, and EMEA Head of Immunology and Transplant. Before joining Astellas, Mr. Barretto-Ko held increasingly senior commercial positions with the Roche Group in the United States and United Kingdom, across various therapeutic areas including Oncology, Hematology, Virology, Immunology, and Infectious Diseases.

Mr. Barretto-Ko earned a Bachelor of Science in Biological Sciences with Honors from Cornell University and a Master of Business Administration from Yale University. In addition, Mr. Barretto-Ko served as a Sloan Fellow for Innovation and Global Leadership at the MIT Sloan School of Management, where he was awarded a Master of Science degree in Management. He is a board member of Americares, a health-focused relief and development organization that serves people affected by poverty or disaster with life-changing medicine and health programs.

On November 4, 2021 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, reported that Maurice Zauderer, Ph.D., President and Chief Executive Officer, is scheduled to present virtually at the 12th Annual Jefferies London Healthcare Conference and invites investors to participate in virtual one-on-one meetings on Thursday and Friday, November 18th and 19th (Press release, Vaccinex, NOV 4, 2021, View Source [SID1234594566]). Please see Presentation details below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

12th Annual Jefferies London Healthcare Conference
Date: November 18th to 19th, 2021
Time: Virtual presentation available Thursday, November 18 at 8:00am GMT/3:00am ET through Friday, November 19 at 5:00pm GMT / 12:00pm ET
Presenter: Maurice Zauderer, Ph.D., President and Chief Executive Officer
Webcast Link: View Source;group=TbkBHEif
Replay: The presentation and a replay of the webcast will be available on Vaccinex’s website shortly after the event at: View Source
Please contact your Jefferies representative or Vaccinex if you would like to participate in a virtual one-on-one meeting during the conference.

For more information about the Jefferies London Healthcare Conference, please refer to the Jefferies conference website. Vaccinex’s presentation will also be available on the Jefferies website for 30 days after the conference.